List of works - Hareth Nahi

A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor

scientific article published on 24 August 2018

A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.

scientific article published on 25 January 2013

A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family

scientific article published on 24 February 2015

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

scientific article published on 11 January 2011

Absence of a common founder mutation in patients with co-occurring myelodysplastic syndrome and plasma cell disorder

scientific article published on 29 October 2020

Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma.

scientific article published on 8 March 2018

Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients

scientific article published on 15 November 2013

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

scientific article published on 22 November 2018

An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients.

scientific article published on 25 August 2008

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

scientific article published in Nature Communications

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

scientific article published on 11 January 2008

Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery

scientific article published on 22 July 2011

Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.

scientific article

Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement

scientific article published on 07 March 2014

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

scientific article published on 4 April 2017

Bortezomib Re-treatment in Patients with Multiple Myeloma (MM). A Real World Medical Practice Experience from a Swedish National Registry

scientific article published on 26 October 2014

Case Report: Treatment of light-chain amyloidosis with daratumumab monotherapy in two patients

scientific article

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

scientific article

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

scientific article published on 29 September 2016

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

scientific article published on 22 August 2019

Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.

scientific article

Clinical impact of chromosomal aberrations in multiple myeloma ⬇️

scientific article published on December 15, 2010

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor

scientific article published on 26 August 2010

Comparative Real World Effectiveness of Novel Agents Versus Conventional Therapies in Multiple Myeloma Patients in Sweden

scientific article published on 26 October 2014

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

scientific article

Constitutional inv(3) in myelodysplastic syndromes

scientific article published on 09 June 2010

Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.

scientific article

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

scientific article

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma

scientific article published on 17 September 2015

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens

scientific article published on 14 September 2006

Direct evidence for a polygenic etiology in familial multiple myeloma

scientific article published on 07 April 2017

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.

scientific article published on 30 December 2016

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.

scientific article

Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.

scientific article published on 6 April 2017

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

scientific article published on 20 May 2016

European perspective on multiple myeloma treatment strategies in 2014

scientific article

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells

scientific article published on 10 January 2019

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.

scientific article published on 18 March 2010

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma ⬇️

scientific article

Health resource utilization associated with skeletal-related events: results from a retrospective European study

scientific article published on 08 August 2015

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

scientific article published in Nature Communications

IgM myeloma: A multicenter retrospective study of 134 patients

scientific article published on 6 April 2017

Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype

scientific article published on 23 August 2014

Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.

scientific article published in July 2009

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT.

scientific article

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.

scientific article

Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.

scientific article

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma

scientific article published on 13 February 2019

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.

scientific article published on 19 April 2018

Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival

scientific article

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

scientific article published on 22 July 2018

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

scientific article published on 26 March 2011

Mutated and non-mutated TP53 as targets in the treatment of leukaemia.

scientific article

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

scientific article published on 12 May 2017

Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry

scientific article published on 16 November 2019

Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR).

scientific article published on 7 December 2017

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.

scientific article published on 3 October 2016

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

scientific article

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

scientific article published on 25 November 2017

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

scientific article published on 25 April 2016

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks

scientific article published on 29 September 2011

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma

scientific article published on 09 May 2018

Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.

scientific article published on 16 March 2015

Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis

scientific article published on 02 January 2020

Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach

scientific article

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

scientific article published on 18 September 2019

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

scientific article published on 03 July 2019

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

scientific article published on 23 March 2020

Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation

scientific article published on 29 April 2011

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.

scientific article published in October 2014

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

scientific article

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

scientific article published on 30 March 2012

The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.

scientific article published on 25 October 2007

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.

scientific article

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

scientific article published on 20 October 2017

The prognostic significance of 8p21 deletion in multiple myeloma

scientific article published on 11 November 2008

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment

scientific article

Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia

scientific article published on 01 July 2007

Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?

scientific article published on 06 October 2019

Transmission of chronic lymphocytic leukaemia from a blood stem cell sibling donor to the recipient

scientific article published on 01 December 2008

Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT)

scientific article published on 26 October 2014

Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT

scientific article published on 16 April 2020

Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma

scientific article published on 07 July 2019

Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study

scientific article published on 01 July 2005

Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma

scientific article

List of works by Hareth Nahi

A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor

A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.

A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

Absence of a common founder mutation in patients with co-occurring myelodysplastic syndrome and plasma cell disorder

Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma.

Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients.

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery

Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.

Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

Bortezomib Re-treatment in Patients with Multiple Myeloma (MM). A Real World Medical Practice Experience from a Swedish National Registry

Case Report: Treatment of light-chain amyloidosis with daratumumab monotherapy in two patients

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.

Clinical impact of chromosomal aberrations in multiple myeloma ⬇️

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor

Comparative Real World Effectiveness of Novel Agents Versus Conventional Therapies in Multiple Myeloma Patients in Sweden

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

Constitutional inv(3) in myelodysplastic syndromes

Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens

Direct evidence for a polygenic etiology in familial multiple myeloma

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.

Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

European perspective on multiple myeloma treatment strategies in 2014

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma ⬇️

Health resource utilization associated with skeletal-related events: results from a retrospective European study

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

IgM myeloma: A multicenter retrospective study of 134 patients

Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype

Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT.

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.

Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.

Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

Mutated and non-mutated TP53 as targets in the treatment of leukaemia.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry

Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR).

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma

Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.

Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis

Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

The prognostic significance of 8p21 deletion in multiple myeloma

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment

Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia

Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?